<DOC>
	<DOCNO>NCT01503242</DOCNO>
	<brief_summary>This phase I trial study side effect best dose yttrium Y 90 anti-CD45 monoclonal antibody BC8 give together fludarabine phosphate total-body irradiation follow donor peripheral blood stem cell transplant treat patient multiple myeloma . Radiolabeled monoclonal antibody , yttrium Y 90 anti-CD45 monoclonal antibody BC8 , find cancer cell carry cancer-killing substance without harm normal cell . Giving chemotherapy drug , fludarabine phosphate , total-body irradiation donor peripheral blood stem cell transplant help stop growth cancer cell help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving yttrium Y 90 anti-CD45 monoclonal antibody BC8 , fludarabine phosphate , total-body irradiation transplant together cyclosporine mycophenolate mofetil transplant may stop happening may effective treatment multiple myeloma .</brief_summary>
	<brief_title>90 Y-BC8-DOTA Monoclonal Antibody , Fludarabine Phosphate , Total-Body Irradiation Followed Donor Peripheral Blood Stem Cell Transplant Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess tissue localization 111In-BC8-DOTA antibody therapy ( Ab ) establish reproducibly favorable biodistribution . II . To estimate maximum tolerate dose ( MTD ) radiation deliver via 90Y-BC8-DOTA Ab combine fludarabine phosphate ( FLU ) 2 Gy total-body irradiation ( TBI ) preparative regimen follow human leukocyte antigen ( HLA ) -matched , relate unrelated hematopoietic cell transplant ( HCT ) patient multiple myeloma . SECONDARY OBJECTIVES : I . To assess potential efficacy approach , within limit phase I study , examine disease response , duration remission , disease free survival ( DFS ) , overall survival ( OS ) . OUTLINE : This dose-escalation study yttrium Y 90 anti-CD45 monoclonal antibody BC8 ( 90Y-BC8 Ab ) . Patients receive 90Y-BC8 Ab intravenously ( IV ) day -12 fludarabine phosphate IV day -4 -2 . Patients undergo TBI allogeneic peripheral blood stem cell transplant day 0 . Patients also receive graft-vs-host disease prophylaxis comprise cyclosporine orally ( PO ) twice daily ( BID ) day -3 56 taper day 180 day -3 100 taper 180 ; mycophenolate mofetil IV PO BID day 0-27 , 0-40 taper 96 . After completion study treatment , patient follow every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must history symptomatic myeloma require treatment meet one follow requirement : Have least 1 high risk feature diagnosis ( include deletion 13 hypodiploidy conventional cytogenetics , ( 4 ; 14 ) , ( 14 ; 16 ) deletion 17 fluorescence situ hybridization [ FISH ] , beta 2 microglobulin &gt; 3.5 , lactate dehydrogenase [ LDH ] great 1.5 x upper limit normal [ ULN ] , history plasma cell leukemia ) ( prior chemotherapy ) ; OR Have progressive disease primary therapy without prior autologous stem cell transplant ; OR Have persistent progressive disease follow autologous transplant ; acceptable patient second transplant disease reduction Bone marrow cellularity &gt; = 50 % age define normal value core biopsy ; cellularity must evaluate within 90 day dosimetry infusion least 21 day receive cytoreductive/myelosuppressive chemotherapy Eastern Cooperative Oncology Group ( ECOG ) = &lt; 2 Measured creatinine clearance &gt; 50 ml/min estimate creatinine clearance &gt; 50 ml/min For female childbearing potential , must negative pregnancy test Patients must human leukocyte antigen ( HLA ) ‐matched related donor unrelated donor meet standard Seattle Cancer Care Alliance ( SCCA ) National Marrow Donor Program ( NMDP ) donor center criterion peripheral blood stem cell ( PBSC ) donation , bone marrow donation follow : Related donor relate patient genotypically phenotypically identical HLAA , B , C , DRB1 DQB1 ; phenotypic identity must confirm highresolution type Unrelated donor : Matched HLA‐A , B , C , DRB1 DQB1 high resolution typing ; OR Mismatched single allele without antigen mismatch HLA‐A , B , C define high resolution type otherwise match HLA‐A , B , C , DRB1 DQB1 high resolution type Patient donor pair homozygous mismatch allele , graft rejection vector consider two‐allele mismatch , i.e. , patient A*0101 donor A*0102 , type mismatch allow Donors exclude preexist immunoreactivity identify would jeopardize donor hematopoietic cell engraftment ; determination base standard practice individual institution ; recommended procedure patient 10 10 HLA allele level ( phenotypic ) match obtain panel reactive antibody ( PRA ) screen class I class II antigens patient HCT ; PRA show &gt; 10 % activity , flow cytometric B T cell cytotoxic cross match obtain ; donor exclude cytotoxic cross match assay positive ; patient HLA Class I allele mismatch , flow cytometric B T cell cytotoxic cross match obtain regardless PRA result ; positive anti‐donor cytotoxic crossmatch absolute donor exclusion Ability provide inform consent DONOR : Patients must HLA match donor well standard Seattle Cancer Care Alliance ( SCCA ) National Marrow Donor Program ( NMDP ) /other donor center criterion PBSC donation DONOR : Donors must consent eligible undergo granulocyte colonystimulating factor ( GCSF ) mobilization PBSC harvest ; marrow allow source stem cell study Patients follow organ dysfunction : Left ventricular ejection fraction &lt; 35 % Corrected diffusion capacity carbon monoxide ( DLCO ) &lt; 35 % receive supplemental continuous oxygen Liver abnormality : fulminant liver failure , cirrhosis liver evidence portal hypertension , alcoholic hepatitis , esophageal varix , hepatic encephalopathy , uncorrectable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal liver abscess , biliary obstruction , chronic viral hepatitis , symptomatic biliary disease Pregnant breastfeeding female Circulating antibody mouse immunoglobulin ( HAMA ) Prior allogeneic transplant Plasmacytomas &gt; 1 cm marrow area measure magnetic resonance imaging ( MRI ) extramedullary plasmacytoma ( radiated lesion exempt criterion ) ; patient may receive cytoreductive therapy , include allogeneic stem cell transplant ( ASCT ) ( high risk ) second ASCT ( fail prior ASCT ) achieve disease control , may receive cytoreductive therapy within 30 day dosimetry infusion must bone marrow cellularity meeting inclusion criterion obtain least 21 day cytoreductive/myelosuppressive chemotherapy last administered Prior radiation maximally tolerated level critical normal organ , &gt; 20 Gy prior radiation large area bone marrow ( e.g. , external radiation therapy whole pelvis ) Patients known seropositive human immunodeficiency virus ( HIV ) Fertile men woman unwilling use contraceptive 12 month posttransplant Active central nervous system ( CNS ) disease time treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>